Aquestive Therapeutics, Inc. Amortization of Debt Issuance Costs and Discounts
Aquestive Therapeutics, Inc. (AQST) reported Amortization of Debt Issuance Costs and Discounts of $4.05 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:AmortizationOfFinancingCostsAndDiscounts · last filed 2026-08-11
- Aquestive Therapeutics, Inc. amortization of debt issuance costs and discounts for the quarter ending 2026-06-30 was $1.77M, a 35.70% decline year-over-year.
- Aquestive Therapeutics, Inc. amortization of debt issuance costs and discounts for the quarter ending 2026-03-31 was $2.29M, a 16.87% decline year-over-year.
- Aquestive Therapeutics, Inc. amortization of debt issuance costs and discounts for the quarter ending 2025-12-31 was $2.75M, a 1.85% increase year-over-year.
- Aquestive Therapeutics, Inc. amortization of debt issuance costs and discounts for the quarter ending 2025-09-30 was $2.75M, a 2.81% increase year-over-year.
- Aquestive Therapeutics, Inc. amortization of debt issuance costs and discounts for fiscal 2025 was $10.99M, a 2.62% increase from fiscal 2024.
- Aquestive Therapeutics, Inc. amortization of debt issuance costs and discounts for fiscal 2024 was $10.71M, a 443.31% increase from fiscal 2023.
- Aquestive Therapeutics, Inc. amortization of debt issuance costs and discounts for fiscal 2023 was $1.97M, a 817.21% increase from fiscal 2022.
- Aquestive Therapeutics, Inc. amortization of debt issuance costs and discounts for fiscal 2022 was $215.00K, a 94.24% decline from fiscal 2021.
| Period end | Amortization of Debt Issuance Costs and Discounts 3 month | Amortization of Debt Issuance Costs and Discounts 6 month | Amortization of Debt Issuance Costs and Discounts 9 month | Amortization of Debt Issuance Costs and Discounts 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $4.05M 10-Q · filed 2026-08-11 | $6.80M derived: sum of 3 quarters · filed 2026-08-11 | $9.55M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $2.29M 10-Q · filed 2026-05-13 | $5.04M derived: sum of 2 quarters · filed 2026-05-13 | $7.78M derived: sum of 3 quarters · filed 2026-05-13 | $10.53M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $2.75M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $5.50M derived: sum of 2 quarters · filed 2026-03-04 | $8.24M derived: sum of 3 quarters · filed 2026-08-11 | $10.99M 10-K · filed 2026-03-04 |
| 2025-09-30 | $2.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $5.50M derived: sum of 2 quarters · filed 2026-08-11 | $8.25M 10-Q · filed 2025-11-05 | $10.95M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $2.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $5.50M 10-Q · filed 2026-08-11 | $8.20M derived: sum of 3 quarters · filed 2026-08-11 | $10.87M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $2.75M 10-Q · filed 2026-05-13 | $5.45M derived: sum of 2 quarters · filed 2026-05-13 | $8.12M derived: sum of 3 quarters · filed 2026-05-13 | $10.79M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $2.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $5.37M derived: sum of 2 quarters · filed 2026-03-04 | $8.04M derived: sum of 3 quarters · filed 2026-03-04 | $10.71M 10-K · filed 2026-03-04 |
| 2024-09-30 | $2.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $5.34M derived: sum of 2 quarters · filed 2025-11-05 | $8.02M 10-Q · filed 2025-11-05 | $9.81M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $2.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $5.34M 10-Q · filed 2025-08-11 | $7.14M derived: sum of 3 quarters · filed 2025-08-11 | $7.20M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | $2.67M 10-Q · filed 2025-05-12 | $4.47M derived: sum of 2 quarters · filed 2025-05-12 | $4.53M derived: sum of 3 quarters · filed 2025-05-12 | $4.59M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $1.80M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | $1.86M derived: sum of 2 quarters · filed 2025-03-05 | $1.92M derived: sum of 3 quarters · filed 2025-03-05 | $1.97M 10-K · filed 2025-03-05 |
| 2023-09-30 | $59.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | $118.00K derived: sum of 2 quarters · filed 2024-11-04 | $174.00K 10-Q · filed 2024-11-04 | $232.00K derived: sum of 4 quarters · filed 2024-11-04 |
| 2023-06-30 | $59.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $115.00K 10-Q · filed 2024-08-06 | $173.00K derived: sum of 3 quarters · filed 2024-08-06 | $221.00K derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $56.00K 10-Q · filed 2024-05-07 | $114.00K derived: sum of 2 quarters · filed 2024-05-07 | $162.00K derived: sum of 3 quarters · filed 2024-05-07 | $231.00K derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $58.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | $106.00K derived: sum of 2 quarters · filed 2024-03-05 | $175.00K derived: sum of 3 quarters · filed 2024-03-05 | $215.00K 10-K · filed 2024-03-05 |
| 2022-09-30 | $48.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $117.00K derived: sum of 2 quarters · filed 2023-11-06 | $157.00K 10-Q · filed 2023-11-06 | $284.00K derived: sum of 4 quarters · filed 2023-11-06 |
| 2022-06-30 | $69.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $109.00K 10-Q · filed 2023-08-07 | $236.00K derived: sum of 3 quarters · filed 2023-08-07 | $1.45M derived: sum of 4 quarters · filed 2023-08-07 |
| 2022-03-31 | $40.00K 10-Q · filed 2023-05-02 | $167.00K derived: sum of 2 quarters · filed 2023-05-02 | $1.38M derived: sum of 3 quarters · filed 2023-05-02 | $2.59M derived: sum of 4 quarters · filed 2023-05-02 |
| 2021-12-31 | $127.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $1.34M derived: sum of 2 quarters · filed 2023-03-31 | $2.55M derived: sum of 3 quarters · filed 2023-03-31 | $3.73M 10-K · filed 2023-03-31 |
| 2021-09-30 | $1.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01 | $2.42M derived: sum of 2 quarters · filed 2022-11-01 | $3.60M 10-Q · filed 2022-11-01 | $4.43M derived: sum of 4 quarters · filed 2022-11-01 |
| 2021-06-30 | $1.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-02 | $2.39M 10-Q · filed 2022-08-02 | $3.22M derived: sum of 3 quarters · filed 2022-08-02 | $3.81M derived: sum of 4 quarters · filed 2022-08-02 |
| 2021-03-31 | $1.18M 10-Q · filed 2022-05-04 | $2.01M derived: sum of 2 quarters · filed 2022-05-04 | $2.60M derived: sum of 3 quarters · filed 2022-05-04 | $3.19M derived: sum of 4 quarters · filed 2022-05-04 |
| 2020-12-31 | $829.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08 | $1.42M derived: sum of 2 quarters · filed 2022-03-08 | $2.00M derived: sum of 3 quarters · filed 2022-03-08 | $2.59M 10-K · filed 2022-03-08 |
| 2020-09-30 | $591.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | $1.17M derived: sum of 2 quarters · filed 2021-11-02 | $1.76M 10-Q · filed 2021-11-02 | $2.35M derived: sum of 4 quarters · filed 2021-11-02 |
| 2020-06-30 | $583.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-03 | $1.17M 10-Q · filed 2021-08-03 | $1.76M derived: sum of 3 quarters · filed 2021-08-03 | $2.31M derived: sum of 4 quarters · filed 2021-08-03 |
| 2020-03-31 | $584.00K 10-Q · filed 2021-05-04 | $1.18M derived: sum of 2 quarters · filed 2021-05-04 | $1.73M derived: sum of 3 quarters · filed 2021-05-04 | $2.12M derived: sum of 4 quarters · filed 2021-05-04 |
| 2019-12-31 | $591.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-09 | $1.15M derived: sum of 2 quarters · filed 2021-03-09 | $1.54M derived: sum of 3 quarters · filed 2021-03-09 | $1.93M 10-K · filed 2021-03-09 |
| 2019-09-30 | $557.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | $949.00K derived: sum of 2 quarters · filed 2020-11-04 | $1.34M 10-Q · filed 2020-11-04 | $1.74M derived: sum of 4 quarters · filed 2020-11-04 |
| 2019-06-30 | $392.00K 10-Q · filed 2019-08-06 | $781.00K 10-Q · filed 2020-08-04 | $1.18M derived: sum of 3 quarters · filed 2020-05-05 | $1.55M derived: sum of 4 quarters · filed 2020-05-05 |
| 2019-03-31 | $389.00K 10-Q · filed 2020-05-05 | $788.00K derived: sum of 2 quarters · filed 2020-05-05 | $1.16M derived: sum of 3 quarters · filed 2020-05-05 | $1.63M derived: sum of 4 quarters · filed 2020-05-05 |
| 2018-12-31 | $399.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-11 | $773.00K derived: sum of 2 quarters · filed 2020-03-11 | $1.24M derived: sum of 3 quarters · filed 2020-03-11 | $1.70M 10-K · filed 2020-03-11 |
| 2018-09-30 | $374.00K 10-Q · filed 2018-11-06 | $839.00K derived: sum of 2 quarters · filed 2019-08-06 | $1.30M 10-Q · filed 2019-11-05 | $1.77M derived: sum of 4 quarters · filed 2019-08-06 |
| 2018-06-30 | $465.00K 10-Q · filed 2019-08-06 | $923.00K 10-Q · filed 2019-08-06 | $1.39M derived: sum of 3 quarters · filed 2019-08-06 | $1.86M derived: sum of 4 quarters · filed 2019-08-06 |
| 2018-03-31 | $458.00K 10-Q · filed 2019-05-08 | $927.00K derived: sum of 2 quarters · filed 2019-05-08 | $1.40M derived: sum of 3 quarters · filed 2019-05-08 | $1.86M derived: sum of 4 quarters · filed 2019-05-08 |
| 2017-12-31 | $469.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-14 | $940.00K derived: sum of 2 quarters · filed 2019-03-14 | $1.40M derived: sum of 3 quarters · filed 2019-03-14 | $1.86M 10-K · filed 2019-03-14 |
| 2017-09-30 | $471.00K 10-Q · filed 2018-11-06 | $934.00K derived: sum of 2 quarters · filed 2018-11-06 | $1.39M 10-Q · filed 2018-11-06 | |
| 2017-06-30 | $463.00K 10-Q · filed 2018-09-04 | $920.00K 10-Q · filed 2018-09-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |